US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
15 nov. 2021 06h00 HE
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC...
US DoD Naval Medical Research Center Clinical Update
10 nov. 2021 06h00 HE
|
Immuron Limited
Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed.IND submission to the U.S. Food and Drug administration...
IMM-124E – Demonstrates Antiviral T-Cell Immunity
08 oct. 2021 06h00 HE
|
Immuron Limited
Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical...
Immuron Director resignation
23 sept. 2021 23h00 HE
|
Immuron Limited
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
Immuron planned Acquisition of R&D Vaccine Company
23 sept. 2021 09h00 HE
|
Immuron Limited
MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
13 mai 2021 06h00 HE
|
Immuron Limited
Key Points Monash University Research Update on SARS-CoV-2 programBiomedicine Discovery Institute initiates program to isolate and identify the inhibitory molecule/s in IMM-124E Appointment of Chief...
Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
11 janv. 2021 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral...
Immuron SARS-CoV-2 Research Agreement with Monash University
15 déc. 2020 06h00 HE
|
Immuron Limited
Key Points Immuron’s Hyper-immune Bovine Colostrum, used to manufacture Travelan® and Protectyn®, demonstrated antiviral activity against the SARS-CoV-2/COVID-19 virus in laboratory studies.A New...
Immuron Receives AUD $358,280 R&D Tax Concession Refund
24 nov. 2020 06h00 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...
US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine
11 nov. 2020 06h00 HE
|
Immuron Limited
Key Points NMRC demonstrated functional antibodies in new oral therapeutic targeting Campylobacter and ETECImmuron executes a Research Agreement with PCI Clinical Services to manufacture drug...